FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2087057667> ?p ?o ?g. }

• W2087057667 endingPage "90" @default.
• W2087057667 startingPage "86" @default.
• W2087057667 abstract "Thirty-four girls with precocious puberty (27 idiopathic, 6 cerebral, 1 McCune-Albright syndrome) were treated with cyproterone acetate (CPA) for 1.2-8.4 years (3.71 ± 0.31; mean ± SEM) at a daily dosage of 66-150 mg/m2 (103.7 ± 6.2). The mean chronological age (CA) and bone age at the beginning of treatment were 5.99 ± 0.31 and 8.6 ± 0.39 years, respectively, and 9.78 ± 0.19 and 12.44 ± 0.22 years, respectively, at the end of therapy. At the last evaluation, mean CA was 14.23 ± 0.4 years, and 32 girls had reached final height. The control group consisted of 10 girls with idiopathic precocious puberty who, at their parents’ request, were not treated. Mean CA at the onset of pubertal signs was 6.05 ± 0.25 years. All patients had reached final height at the time of the last observation. There was no significant difference between final height of treated (152.43 ± 1.36 cm) and untreated (149.55 ± 1.99 cm) girls. Final height was significantly lower than target height in both treated (155.08 ± 0.92 cm; p < 0.025) and untreated (156.45 ± 1.29 cm; p < 0.0005) patients, but the mean height of treated patients is nearer to target height than that of untreated ones. A positive correlation was found between final height and target height both in treated (p < 0.005) and untreated (p < 0.05) patients. After the discontinuation of CPA treatment all girls resumed the progressive course of puberty. Menstruation was regular and normal in 27 cases and irregular in the remaining 7, of whom 4 showed additional hormonal and clinical evidence of polycystic ovarian disease (PCOD). Menses were regular in 8 and irregular in 2 untreated patients, of whom 1 also showed PCOD. It is concluded that CPA treatment slightly improved the statural growth of patients with precocious puberty. The altered gonadal function observed in adulthood in these patients is probably not due to CPA administration. A longer follow-up is needed in patients with central precocious puberty in order to detect the presence of PCOD." @default.
• W2087057667 created "2016-06-24" @default.
• W2087057667 creator A5000402138 @default.
• W2087057667 creator A5004832352 @default.
• W2087057667 creator A5025889328 @default.
• W2087057667 creator A5036034386 @default.
• W2087057667 creator A5047259990 @default.
• W2087057667 creator A5066721377 @default.
• W2087057667 creator A5071751548 @default.
• W2087057667 creator A5082946143 @default.
• W2087057667 date "1992-01-01" @default.
• W2087057667 modified "2023-10-07" @default.
• W2087057667 title "Final Height Attainment and Gonadal Function in Girls with Precocious Puberty Treated with Cyproterone Acetate" @default.
• W2087057667 doi "https://doi.org/10.1159/000182288" @default.
• W2087057667 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/1478628" @default.
• W2087057667 hasPublicationYear "1992" @default.
• W2087057667 type Work @default.
• W2087057667 sameAs 2087057667 @default.
• W2087057667 citedByCount "18" @default.
• W2087057667 countsByYear W20870576672012 @default.
• W2087057667 countsByYear W20870576672015 @default.
• W2087057667 countsByYear W20870576672017 @default.
• W2087057667 crossrefType "journal-article" @default.
• W2087057667 hasAuthorship W2087057667A5000402138 @default.
• W2087057667 hasAuthorship W2087057667A5004832352 @default.
• W2087057667 hasAuthorship W2087057667A5025889328 @default.
• W2087057667 hasAuthorship W2087057667A5036034386 @default.
• W2087057667 hasAuthorship W2087057667A5047259990 @default.
• W2087057667 hasAuthorship W2087057667A5066721377 @default.
• W2087057667 hasAuthorship W2087057667A5071751548 @default.
• W2087057667 hasAuthorship W2087057667A5082946143 @default.
• W2087057667 hasConcept C126322002 @default.
• W2087057667 hasConcept C134018914 @default.
• W2087057667 hasConcept C187212893 @default.
• W2087057667 hasConcept C2776306840 @default.
• W2087057667 hasConcept C2777155358 @default.
• W2087057667 hasConcept C2777911890 @default.
• W2087057667 hasConcept C2778367240 @default.
• W2087057667 hasConcept C2778715236 @default.
• W2087057667 hasConcept C71315377 @default.
• W2087057667 hasConcept C71924100 @default.
• W2087057667 hasConcept C89551170 @default.
• W2087057667 hasConceptScore W2087057667C126322002 @default.
• W2087057667 hasConceptScore W2087057667C134018914 @default.
• W2087057667 hasConceptScore W2087057667C187212893 @default.
• W2087057667 hasConceptScore W2087057667C2776306840 @default.
• W2087057667 hasConceptScore W2087057667C2777155358 @default.
• W2087057667 hasConceptScore W2087057667C2777911890 @default.
• W2087057667 hasConceptScore W2087057667C2778367240 @default.
• W2087057667 hasConceptScore W2087057667C2778715236 @default.
• W2087057667 hasConceptScore W2087057667C71315377 @default.
• W2087057667 hasConceptScore W2087057667C71924100 @default.
• W2087057667 hasConceptScore W2087057667C89551170 @default.
• W2087057667 hasIssue "3" @default.
• W2087057667 hasLocation W20870576671 @default.
• W2087057667 hasLocation W20870576672 @default.
• W2087057667 hasOpenAccess W2087057667 @default.
• W2087057667 hasPrimaryLocation W20870576671 @default.
• W2087057667 hasRelatedWork W1969749533 @default.
• W2087057667 hasRelatedWork W2066746614 @default.
• W2087057667 hasRelatedWork W2093272887 @default.
• W2087057667 hasRelatedWork W2131968197 @default.
• W2087057667 hasRelatedWork W2149228304 @default.
• W2087057667 hasRelatedWork W2386465299 @default.
• W2087057667 hasRelatedWork W242146478 @default.
• W2087057667 hasRelatedWork W2467019772 @default.
• W2087057667 hasRelatedWork W283594982 @default.
• W2087057667 hasRelatedWork W2725118148 @default.
• W2087057667 hasVolume "37" @default.
• W2087057667 isParatext "false" @default.
• W2087057667 isRetracted "false" @default.
• W2087057667 magId "2087057667" @default.
• W2087057667 workType "article" @default.